A pharmacogenomic evaluation of migraine therapy

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 12, 2007, Pages 1821-1835

  Johnson, Matthew P ^a,b   Fernandez, Francesca ^a   Colson, Natalie J ^a   Griffiths, Lyn R ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Association; Linkage; Migraine; Migraine trait component; Pharmacogenomic

Indexed keywords

ACETYLSALICYLIC ACID; ALMOTRIPTAN; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIMIGRAINE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN A; CALCIUM ANTAGONIST; CATECHOL METHYLTRANSFERASE; DICLOFENAC; DIHYDROERGOTAMINE MESILATE; DOPAMINE TRANSPORTER; ELETRIPTAN; ERGOT ALKALOID; ERGOTAMINE TARTRATE; FROVATRIPTAN; GLUTATHIONE TRANSFERASE; IBUPROFEN; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; RIZATRIPTAN; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; SUMATRIPTAN; TRIPTAN DERIVATIVE; UNINDEXED DRUG; ZOLMITRIPTAN;

CHROMOSOME 11Q; CHROMOSOME 14Q; CHROMOSOME 15Q; CHROMOSOME 17P; CHROMOSOME 18Q; CHROMOSOME 19P; CHROMOSOME 1Q; CHROMOSOME 4Q; CHROMOSOME 5Q; CHROMOSOME 6P; CHROMOSOME XQ; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DROWSINESS; FATIGUE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HEADACHE; HUMAN; IDIOPATHIC DISEASE; INDIVIDUALIZATION; MIGRAINE; MIGRAINE WITH AURA; NAUSEA; NEUROLOGIC DISEASE; PHARMACOGENOMICS; PHENOTYPIC VARIATION; PHONOPHOBIA; PHOTOPHOBIA; REVIEW; SIDE EFFECT; SLEEP DISORDER; SYMPTOMATOLOGY; TREATMENT PLANNING; VOMITING; WEIGHT GAIN;

CHROMOSOME MAPPING; GENETIC PREDISPOSITION TO DISEASE; GENETIC RESEARCH; GENOME; HUMANS; MIGRAINE DISORDERS; PHARMACOGENETICS; PHENOTYPE; SEROTONIN AGONISTS;

EID: 34548283972     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.12.1821     Document Type: Review

References (169)

1. HEADACHE CLASSIFICATION COMMITTEE OF THE INTERNATIONAL HEADACHE SOCIETY: Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia (1988) 8(Suppl. 7):1-96.
2. HEADACHE CLASSIFICATION SUBCOMMITTEE OF THE INTERNATIONAL HEADACHE SOCIETY: The international classification of headache disorders, 2nd Edition. Cephalalgia (2004) 24(Suppl. 1):1-160.
3. WORLD HEALTH ORGANIZATION: The World Health Report 2001: Mental Health: New Understanding, New Hope. (Ed.), World Health Organization, Geneva (2001):xviii, 178.
4. LANCE JW, GOADSBY PJ: Mechanism and Management of Headache. (Ed.), Butterworth-Heinemann, Oxford (1998):317.
5. PIETROBON D, STRIESSNIG J: Neurobiology of migraine. Nat. Rev. Neurosci. (2003) 4(5):386-398.
6. GOADSBY PJ, LIPTON RB, FERRARI MD: Migraine - current understanding and treatment. N. Engl. J. Med. (2002) 346(4):257-270.
7. STEWART WF, LIPTON RB, CELENTANO DD, REED ML: Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA (1992) 267(1):64-69.
8. STEWART WF, LIPTON RB, LIBERMAN J: Variation in migraine prevalence by race. Neurology (1996) 47(1):52-59.
9. JOUTEL A, DUCROS A, VAHEDI K et al.: Genetic heterogeneity of familial hemiplegic migraine. Am. J. Hum. Genet. (1994) 55(6):1166-1172.
10. OPHOFF RA, VAN EIJK R, SANDKUIJL LA et al.: Genetic heterogeneity of familial hemiplegic migraine. Genomics (1994) 22(1):21-26.
11. PEROUTKA SJ: Genetic basis of migraine. Clin. Neurosci. (1998) 5(1):34-37.
12. DIENER HC, LIMMROTH V: Advances in pharmacological treatment of migraine. Expert Opin. Investig. Drugs (2001) 10(10):1831-1845.
13. GOADSBY PJ: Advances in the understanding of headache. Br. Med. Bull. (2005) 73-74:83-92.
14. FERRARI MD, ROON KI, LIPTON RB, GOADSBY PJ: Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet (2001) 358(9294):1668-1675.
15. DAHLÖF CG, LINDE M, KEREKES E: Zolmitriptan nasal spray provides fast relief of migraine symptoms and is preferred by patients: a Swedish study of preference in clinical practice. J. Headache Pain (2004) 5(4):237-242.
16. SILBERSTEIN SD: Preventive treatment of migraine. Trends Pharmacol. Sci. (2006) 27(8):410-415.
17. TFELT-HANSEN P, HENRY P, MULDER LJ et al.: The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet (1995) 346(8980):923-926.
18. DIENER HC, BUSSONE G, DE LIANO H et al.: Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia (2004) 24(11):947-954.
19. GARCIA GD, GOFF JM Jr, HADRO NC, O'DONNELL SD, GREATOREX PS: Chronic ergot toxicity: a rare cause of lower extremity ischemia. J. Vasc. Surg. (2000) 31(6):1245-1247.
20. EVERS S, GRALOW I, BAUER B et al.: Sumatriptan and ergotamine overuse and drug-induced headache: a clinicoepidemiologic study. Clin. Neuropharmacol. (1999) 22(4):201-206.
21. LAMPL C, BUZATH A, YAZDI K, SANDOR PS: Ergot and triptan overuse in Austria - an evaluation of clinical data and cost. Cephalalgia (2002) 22(10):807-811.
22. GOADSBY PJ: Migraine: emerging treatment options for preventive and acute attack therapy. Expert Opin. Emerg. Drugs (2006) 11(3):419-427.
23. LEONARDI M, STEINER TJ, SCHER AT, LIPTON RB: The global burden of migraine: measuring disability in headache disorders with WHO's Classification of Functioning, Disability and Health (ICF). J. Headache Pain (2005) 6(6):429-440.
24. WESSMAN M, KALLELA M, KAUNISTO MA et al.: A susceptibility locus for migraine with aura, on chromosome 4q24. Am. J. Hum. Genet. (2002) 70(3):652-662.
25. BJORNSSON A, GUDMUNDSSON G, GUDFINNSSON E et al.: Localization of a gene for migraine without aura to chromosome 4q21. Am. J. Hum. Genet. (2003) 73(6):986-993.
26. GERVIL M, ULRICH V, KAPRIO J, OLESEN J, RUSSELL MB: The relative role of generic and environmental factors in migraine without aura. Neurology (1999) 53(5):995-999.
27. GERVIL M, ULRICH V, KYVIK KO, OLESEN J, RUSSELL MB: Migraine without aura: a population-based twin study. Ann. Neurol. (1999) 46(4):606-611.
28. ULRICH V, GERVIL M, KYVIK KO, OLESEN J, RUSSELL MB: Evidence of a genetic factor in migraine with aura: a population-based Danish twin study. Ann. Neurol. (1999) 45(2):242-246.
29. RUSSELL MB, HILDEN J, SORENSEN SA, OLESEN J: Familial occurrence of migraine without aura and migraine with aura. Neurology (1993) 43(7):1369-1373.
30. RUSSELL MB, ISELIUS L, OLESEN J: Migraine without aura and migraine with aura are inherited disorders. Cephalalgia (1996) 16(5):305-309.
31. RUSSELL MB, OLESEN J: Increased familial risk and evidence of genetic factor in migraine. BMJ (1995) 311(7004):541-544.
32. NYHOLT DR, GILLESPIE NG, HEATH AC et al.: Latent class and genetic analysis does not support migraine with aura and migraine without aura as separate entities. Genet. Epidemiol. (2004) 26(3):231-244.
33. KALLELA M, WESSMAN M, HAVANKA H, PALOTIE A, FARKKILA M: Familial migraine with and without aura: clinical characteristics and co-occurrence. Eur. J. Neurol. (2001) 8(5):441-449.
34. LAUNER LJ, TERWINDT GM, FERRARI MD: The prevalence and characteristics of migraine in a population-based cohort: the GEM study. Neurology (1999) 53(3):537-542.
35. RASMUSSEN BK: Migraine and tension-type headache in a general population: precipitating factors, female hormones, sleep pattern and relation to lifestyle. Pain (1993) 53(1):65-72.
36. LIPTON RB, STEWART WF: Migraine in the United States: a review of epidemiology and health care use. Neurology (1993) 43(6 Suppl. 3):S6-S10.
37. NYHOLT DR, DAWKINS JL, BRIMAGE PJ et al.: Evidence for an X-linked genetic component in familial typical migraine. Hum. Mol. Genet. (1998) 7(3):459-463.
38. NYHOLT DR, CURTAIN RP, GRIFFITHS LR: Familial typical migraine: significant linkage and localization of a gene to Xq24-28. Hum. Genet. (2000) 107(1):18-23.
39. CARLSSON A, FORSGREN L, NYLANDER PO et al.: Identification of a susceptibility locus for migraine with and without aura on 6p12.2-p21.1. Neurology (2002) 59(11):1804-1807.
40. SORAGNA D, VETTORI A, CARRARO G et al.: A locus for migraine without aura maps on chromosome 14q21.2-q22.3. Am. J. Hum. Genet. (2003) 72(1):161-167.
41. NYHOLT DR, LEA RA, GOADSBY PJ, BRIMAGE PJ, GRIFFITHS LR: Familial typical migraine:, linkage to chromosome 19p13 and evidence for genetic heterogeneity. Neurology (1998) 50(5):1428-1432.
42. JOUTEL A, BOUSSER MG, BIOUSSE V et al.: A gene for familial hemiplegic migraine maps to chromosome 19. Nat. Genet. (1993) 5(1):40-45.
43. LEA RA, SHEPHERD AG, CURTAIN RP et al.: A typical migraine susceptibility region localizes to chromosome 1q31. Neurogenetics (2002) 4(1):17-22.
44. CADER ZM, NOBLE-TOPHAM S, DYMENT DA et al.: Significant linkage to migraine with aura on chromosome 11q24. Hum. Mol. Genet. (2003) 12(19):2511-2517.
45. CUTRER FM, MOSKOWITZ MA: Wolff Award 1996. The actions of valproate and neurosteroids in a model of trigeminal pain. Headache (1996) 36(10):579-585.
46. RUSSO L, MARIOTTI P, SANGIORGI E et al.: A new susceptibility locus for migraine with aura in the 15q11-q13 genomic region containing three GABA-A receptor genes. Am. J. Hum. Genet. (2005) 76(2):327-333.
47. LEA RA, NYHOLT DR, CURTAIN RP et al.: A genome-wide scan provides evidence for loci influencing a severe heritable form of common migraine. Neurogenetics (2005) 6(2):67-72.
48. NYHOLT DR, MORLEY KI, FERREIRA MA et al.: Genomewide significant linkage to migrainous headache on chromosome 5q21. Am. J. Hum. Genet. (2005) 77(3):500-512.
49. ANTTILA V, KALLELA M, OSWELL G et al.: Trait components provide tools to dissect the genetic susceptibility of migraine. Am. J. Hum. Genet. (2006) 79(1):85-99.
50. PARDO J, CARRACEDO A, MUNOZ I et al.: Genetic markers: association study in migraine. Cephalalgia (1995) 15(3):200-204.
51. 2A) receptor gene. Cephalalgia (1996) 16(7):463-467.
52. FANCIULLACCI M, ALESSANDRI M, DEL ROSSO A: Dopamine involvement in the migraine attack. Funct. Neurol. (2000) 15(Suppl. 3):171-181.
53. DEL ZOMPO M: Dopaminergic hypersensitivity in migraine: clinical and genetic evidence. Funct. Neurol. (2000) 15(Suppl. 3):163-170.
54. HEINZ A, GOLDMAN D, JONES DW et al.: Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology (2000) 22(2):133-139.
55. MOCHI M, CEVOLI S, CORTELLI P et al.: A genetic association study of migraine with dopamine receptor 4, dopamine transporter and dopamine-β-hydroxylase genes. Neurol. Sci. (2003) 23(6):301-305.
56. DEL ZOMPO M, CHERCHI A, PALMAS MA et al.: Association between dopamine receptor genes and migraine without aura in a Sardinian sample. Neurology (1998) 51(3):781-786.
57. SHEPHERD AG, LEA RA, HUTCHINS C et al.: Dopamine receptor genes and migraine with and without aura: an association study. Headache (2002) 42(5):346-351.
58. MAUDE S, CURTIN J, BREEN G et al.: The - 141C Ins/Del polymorphism of the dopamine D2 receptor gene is not associated with either migraine or Parkinson's disease. Psychiatry Genet. (2001) 11(1):49-52.
59. LEA RA, DOHY A, JORDAN K et al.: Evidence for allelic association of the dopamine β-hydroxylase gene (DBH) with susceptibility to typical migraine. Neurogenetics (2000) 3(1):35-40.
60. PEROUTKA SJ, WILHOIT T, JONES K: Clinical susceptibility to migraine with aura is modified by dopamine D2 receptor (DRD2) NcoI alleles. Neurology (1997) 49(I):201-206.
61. ANTHONY M: Biochemical indices of sympathetic activity in migraine. Cephalalgia (1981) 1(2):83-89.
62. EMIN ERDAL M, HERKEN H, YILMAZ M, BAYAZIT YA: Significance of the catechol-O-methyltransferase gene polymorphism in migraine. Brain Res. Mol. Brain Res. (2001) 94(1-2):193-196.
63. HAGEN K, PETTERSEN E, STOVNER LJ, SKORPEN F, ZWART JA: The association between headache and Val158Met polymorphism in the catechol-O-methyltransferase gene: the HUNT Study. J. Headache Pain (2006) 7(2):70-74.
64. MOSSNER R, FREITAG CM, MARZINIAK M et al.: The functional Val158Met variant of the COMT gene is not associated with migraine with or without aura. J. Headache Pain (2006) 7(3):165-166.
65. ANTHONY M, HINTERBERGER H, LANCE JW: Plasma serotonin in migraine and stress. Arch. Neurol. (1967) 16(5):544-552.
66. DALSGAARD-NIELSEN T, GENEFKE IK: Serotonin (5-hydroxytryptamine) release and uptake in platelets from healthy persons and migrainous patients in attack-free intervals. Headache (1974) 14(1):26-32.
67. KIMBALL RW, FRIEDMAN AP, VALLEJO E: Effect of serotonin in migraine patients. Neurology (1960) 10:107-111.
68. CHUGANI DC, NIIMURA K, CHATURVEDI S et al.: Increased brain serotonin synthesis in migraine. Neurology (1999) 53(7):1473-1479.
69. MOSKOWITZ MA: Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol. Sci. (1992) 13(8):307-311.
70. BREWERTON TD, MURPHY DL, MUELLER EA, JIMERSON DC: Induction of migrainelike headaches by the serotonin agonist m-chlorophenylpiperazine. Clin. Pharmacol. Ther. (1988) 43(6):605-609.
71. 7 receptor in craniovascular vasodilatation: potential impact in migraine. Proc. West Pharmacol. Soc. (1998) 41:247-251.
72. TERRON JA: Is the 5-HT(7) receptor involved in the pathogenesis and prophylactic treatment of migraine? Eur. J. Pharmacol. (2002) 439(1-3):1-11.
73. 7 receptor mediating smooth muscle relaxation in canine cerebral arteries. Br. J. Pharmacol. (1999) 127(3):609-616.
74. 2C, and hSERT polymorphisms. Headache (2004) 44:311-317.
75. 2C receptor gene and migraine. Neuroreport (1997) 8(12):2651-2653.
76. 2A receptor gene with aura in migraine. J. Neurol. Sci. (2001) 188(1-2):99-101.
77. 2C receptor gene as a migraine candidate gene. Am. J. Med. Genet. (2003) 117B(1):86-89.
78. 2A receptor gene 102T/C polymorphism and migraine. J. Neurogenet. (2003) 17(2-3):231-240.
79. 2C receptor genes as candidate genes for migraine. Headache (1996) 36(4):254-258.
80. JOHNSON MP, GRIFFITHS LR: A genetic analysis of serotonergic biosynthetic and metabolic enzymes in migraine using a DNA pooling approach. J. Hum. Genet. (2005) 50(12):607-610.
81. MARZINIAK M, MOSSNER R, BENNINGHOFF J et al.: Association analysis of the functional monoamine oxidase A gene promotor polymorphism in migraine. J. Neural. Transm. (2004) 111(5):603-609.
82. KOTANI K, SHIMOMURA T, SHIMOMURA F, IKAWA S, NANBA E: A polymorphism in the serotonin transporter gene regulatory region and frequency of migraine attacks. Headache (2002) 42(9):893-895.
83. OGILVIE AD, RUSSELL MB, DHALL P et al.: Altered allelic distributions of the serotonin transporter gene in migraine without aura and migraine with aura. Cephalalgia (1998) 18(1):23-26.
84. YILMAZ M, ERDAL ME, HERKEN H et al.: Significance of serotonin transporter gene polymorphism in migraine. J. Neurol. Sci. (2001) 186(1-2):27-30.
85. MATTSSON P, BJELFMAN C, LUNDBERG PO, RANE A: Cytochrome P450 2D6 and glutathione S-transferase M1 genotypes and migraine. Eur. J. Clin. Invest. (2000) 30(4):367-371.
86. KUSUMI M, ISHIZAKI K, KOWA H et al.: Glutathione S-transferase polymorphisms: susceptibility to migraine without aura. Eur. Neurol. (2003) 49(4):218-222.
87. BUZZI MG, TASSORELLI C, NAPPI G: Peripheral and central activation of trigeminal pain pathways in migraine. data from experimental animal models. Cephalalgia (2003) 23(Suppl. 1):1-4.
88. LEE TJ: Nitric oxide and the cerebral vascular function. J. Biomed. Sci. (2000) 7(1):16-26.
89. MARTELLETTI P, BRIOLI G, LULLI P et al.: Tumor necrosis factor B gene polymorphism contributes to susceptibility to migraine without aura. J. Headache Pain (2000) 2:119-122.
90. RAINERO I, GRIMALDI LM, SALANI G et al.: Association between the tumor necrosis factur-α-308 G/A gene polymorphism and migraine. Neurology (2004) 62(1):141-143.
91. COLSON NJ, LEA RA, QUINLAN S, MACMILLAN J, GRIFFITHS LR: The estrogen receptor 1 G594A polymorphism is associated with migraine susceptibility in two independent case/control groups. Neurogenetics (2004) 5:129-133.
92. COLSON NJ, LEA RA, QUINLAN S, MACMILLAN J, GRIFFITHS LR: Investigation of hormone receptor genes in migraine. Neurogenetics (2005) 6(1):17-23.
93. GRECO B, ALLEGRETTO EA, TETEL MJ, BLAUSTEIN JD: Coexpression of ER β with ER α and progestin receptor proteins in the female rat forebrain: effects of estradiol treatment Endocrinology (2001) 142(12):5172-5181.
94. TZOURIO C, EL AMRANI M, POIRIER O et al.: Association between migraine and endothelin type A receptor (ETA-231 MG) gene polymorphism. Neurology (2001) 56(10):1273-1277.
95. HASSELBLATT M, KOHLER J, VOLLES E, EHRENREICH H: Simultaneous monitoring of endothelin-1 and vasopressin plasma levels in migraine. Neuroreport (1999) 10(2):423-425.
96. GALLAI V, SARCHIELLI P, FIRENZE C et al.: Endothelin 1 in migraine and tension-type headache. Acta Neurol. Scand. (1994) 89(1):47-55.
97. KALLELA M, FARKKILA M, SAIJONMAA O, FYHRQUIST F: Endothelin in migraine patients. Cephalalgia (1998) 18(6):329-332.
98. PATERNA S, DI PASQUALE P, COTTONE C et al.: Migraine without aura and ACE-gene deletion polymorphism: is there a correlation? Preliminary findings. Cardiovasc. Drugs Ther. (1997) 11(4):603-604.
99. KOWA H, FUSAYASU E, IJIRI T et al.: Association of the insertion/ deletion polymorphism of the angiotensin I-converting enzyme gene in patients of migraine with aura. Neurosci. Lett. (2005) 374(2):129-131.
100. RIGAT B, HUBERT C, ALHENC-GELAS F et al.: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J. Clin. Invest. (1990) 86(4):1343-1346.
101. PATERNA S, DI PASQUALE P, D'ANGELO A et al.: Angiotensin-converting enzyme gene deletion polymorphism determines an increase in frequency of migraine attacks in patients suffering from migraine without aura. Eur. Neurol. (2000) 43(3):133-136.
102. LEA RA, OVCARIC M, SUNDHOLM J et al.: Genetic variants of angiotensin converting enzyme and methylenetetrahydrofolate reductase may act in combination to increase migraine susceptibility. Brain Res. Mol. Brain Res. (2005) 136(1-2):112-117.
103. KARA I, SAZCI A, ERGUL E, KAYA G, KILIC G: Association of the C677T and A1298C polymorphisms in the 5,10 methylenetetrahydrofolate reductase gene in patients with migraine risk. Brain Res. Mol. Brain Res. (2003) 111(1-2):84-90.
104. KOWA H, YASUI K, TAKESHIMA T et al.: The homozygous C677T mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for migraine. Am. J. Med. Genet. (2000) 96(6):762-764.
105. SCHER AI, TERWINDT GM, VERSCHUREN WM et al.: Migraine and MTHFR C677T genotype in a population-based sample. Ann. Neurol. (2006) 59(2):372-375.
106. KAUNISTO MA, KALLELA M, HAMALAINEN E et al.: Testing of variants of the MTHFR and ESR1 genes in 1798 Finnish individuals fails to confirm the association with migraine with aura. Cephalalgia (2006) 26(12):1462-1472.
107. TIETJEN GE: The relationship of migraine and stroke. Neuroepidemiology (2000) 19(1):13-19.
108. SZOLNOKI Z, SOMOGYVARI F, KONDACS A, SZABO M, FODOR L: Evaluation of the interactions of common genetic mutations in stroke subtypes. J. Neurol. (2002) 249(10):1391-1397.
109. LEA RA, OVCARIC M, SUNDHOLM J SOLYOM L, MACMILLAN J, GRIFFITHS LR: Genetic variants of angiotensin converting enzyme and methylene tetrahydrofolate reductase may act in combination to increase migraine susceptibility. Brain Res. Mol. Brain Res. (2005) 136(1-2)112-117.
110. THOMSEN LL, OLESEN J: Nitric oxide theory of migraine. Clin. Neurosci. (1998) 5(1):28-33.
111. BRUHWYLER J, CHLEIDE E, LIEGEOIS JF, CARREER F: Nitric oxide: a new messenger in the brain. Neurosci. Biobehav. Rev. (1993) 17(4):373-384.
112. BORRONI B, RAO R, LIBERINI P et al.: Endothelial nitric oxide synthase (Glu298Asp) polymorphism is an independent risk factor for migraine with aura. Headache (2006) 46(10):1575-1579.
113. MOCHI M, CEVOLI S, CORTELLI P et al.: Investigation of an LDLR gene polymorphism (19p13.2) in susceptibility to migraine without aura. J. Neurol. Sci. (2003) 213(1-2):7-10.
114. MCCARTHY LC, HOSFORD DA, RILEY JH et al. Single-nucleotide polymorphism alleles in the insulin receptor gene are associated with typical migraine. Genomics (2001) 78(3):135-149.
115. SCHRADER H, STOVNER LJ, HELDE G, SAND T, BOVIM G: Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ (2001) 322(7277):19-22.
116. BENDER WI: ACE inhibitors for prophylaxis of migraine headaches. Headache (1995) 35(8):470-471.
117. TRONVIK E, STOVNER LJ, HELDE G, SAND T, BOVIM G: Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA (2003) 289(1):65-69.
118. RIGAT B, HUBERT C, ALHENC-GELAS F et al.: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J. Clin. Invest. (1990) 86(4):1343-1346.
119. TIRET L, RIGAT B, VISVIKIS S et al.: Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am. J. Hum. Genet. (1992) 51(1):197-205.
120. PATERNA S, DI PASQUALE P, D'ANGELO A et al.: Angiotensin-converting enzyme gene deletion polymorphism determines an increase in frequency of migraine attacks in patients suffering from migraine without aura. Eur. Neurol. (2000) 43(3):133-136.
121. FROSST P, BLOM HJ, MILOS R et al.: A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. (1995) 10(1):111-113.
122. DAS UN: Folic acid says NO to vascular diseases. Nutrition (2003) 19(7-8):686-692.
123. LEE BJ, LIN PT, LIAW YP et al.: Homocysteine and risk of coronary artery disease: folate is the important determinant of plasma homocysteine concentration. Nutrition (2003) 19(7-8):577-583.
124. 12 decreases, but does not normalize, homocysteine and methylmalonic acid in end-stage renal disease: a link with glycine metabolism and possible explanation of hyperhomocysteinemia in end-stage renal disease. Metabolism (2003) 52(2):168-172.
125. SILBERSTEIN SD: Topiramate in migraine prevention: evidence-based medicine from clinical trials. Neurol. Sci. (2004) 25(Suppl. 3):S244-S245.
126. KLAPPER J: Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia (1997) 17(2):103-108.
127. HERING-HANIT R: Baclofen for prevention of migraine. Cephalalgia (1999) 19(6):589-591.
128. WELCH KM, CHABI E, BARTOSH K, ACHAR VS, MEYER JS: Cerebrospinal fluid γ aminobutyric acid levels in migraine. BMJ (1975) 3(5982):516-517.
129. RAMADAN NM: The link between glutamate and migraine. CNS Spectr. (2003) 8(6):446-449.
130. MARTINEZ F, CASTILLO J, RODRIGUEZ JR, LEIRA R, NOYA M: Neuroexcitatory amino acid levels in plasma and cerebrospinal fluid during migraine attacks. Cephalalgia (1993) 15(2):89-93.
131. GALLAI V, ALBERTI A, GALLAI B et al.: Glutamate and nitric oxide pathway in chronic daily headache: evidence from eerebrospinal fluid. Cephalalgia (2003) 23(3):166-174.
132. MARTIN VT, BEHBEHANI M: Ovarian hormones and migraine headache: understanding mechanisms and pathogenesis - Part I. Headache (2006) 46(1):3-23.
133. PECINS-THOMPSON M, BROWN NA, BETHEA CL: Regulation of serotonin re-uptake transporter mRNA expression by ovarian steroids in rhesus macaques. Brain Res. Mol. Brain Res. (1998) 53(1-2):120-129.
134. PECINS-THOMPSON M, BROWN NA, KOHAMA SG, BETHEA CL: Ovarian steroid regulation of tryptophan hydroxylase mRNA expression in rhesus macaques. J. Neurosci. (1996) 16(21):7021-7029.
135. SMITH LJ, HENDERSON JA, ABELL CW, BETHEA CL: Effects of ovarian steroids and raloxifene on proteins that synthesize, transport, and degrade serotonin in the raphe region of macaques. Neuropsychopharmacology (2004) 29(11):2035-2045.
136. HERBISON AE, SIMONIAN SX, THANKY NR, BICKNELL RJ: Oestrogen modulation of noradrenaline neurotransmission. Novartis Found. Symp. (2000) 230:74-85; discussion 85-93.
137. PAU KY, HESS DL, KOHAMA S et al.: Oestrogen upregulates noradrenaline release in the mediobasal hypothalamus and tyrosine hydroxylase gene expression in the brainstem of ovariectomized rhesus macaques. J. Neuroendocrinol. (2000) 12(9):899-909.
138. KARKANIAS GB, ANSONOFF MA, ETGEN AM: Estradiol regulation of α1b-adrenoceptor mRNA in female mt hypothalamus-preoptic area. J. Neuroendocrinol. (1996) 8(6):449-455.
139. KARKANIAS GB, ETGEN AM: Estradiol attenuates α2-adrenoceptor-mediated inhibition of hypothalamic norepinephrine release. J. Neurosci. (1993) 13(8):3448-3455.
140. KARKANIAS GB, PETITTI N, ETGEN AM: Progesterone attenuation of α1-adrenergic receptor stimulation of phosphoinositol hydrolysis in hypothalamus of estrogen-primed female rats. Endocrinology (1995) 136(5):1993-1999.
141. SHUGHRUE PJ, MERCHENTHALER I: Estrogen is more than just a "sex hormone": novel sites for estrogen action in the hippocampus and cerebval cortex. Front. Neuroendocrinol. (2000) 21(1):95-101.
142. B-mediated hyperpolarization of hypothalamic arcuate neurons. J. Neurosci. (1992) 12(7):2745-2750.
143. A receptor single-channel kinetic properties of mouse spinal cord neurons in culture. J. Physiol. (1992) 456:215-245.
144. EPPERSON CN, HAGA K, MASON GF et al. Cortical γ-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study. Arch. Gen. Psychiatry (2002) 59(9):851-858.
145. KRAUSE DN, DUCKLES SP, PELLIGRINO DA: Influence of sex steroid hormones on cerebrovascular function. J. Appl. Physiol. (2006) 101(4):1252-1261.
146. NAPPI RE, SANCES G, BRUNDU B et al.: Estradiol supplementation modulates neuroendocrine response to m-chlorophenylpiperazine in menstrual status migrainosus triggered by oral contraception-free interval. Hum. Reprod. (2005) 20(12):3423-3428.
147. JUNG AC, STAIGER T, SULLIVAN M: The efficacy of selective serotonin reuptake inhibitors for the management of chronic pain. J. Gen. Intern. Med. (1997) 12(6):384-389.
148. SMITS K, SMITS L, PEETERS F et al.: Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors. Int. Clin. Psychopharmacol. (2007) 22(3):137-143.
149. SMITS KM, SMITS LJ, SCHOUTEN JS et al.: Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. Mol. Psychiatry (2004) 9(5):433-441.
150. MOJA PL, CUSI C, STERZI RR, CANEPARI C: Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches. Cochrane Database Syst. Rev. (2005) (3):CD002919.
151. GONDA X, RIHMER Z, JUHASZ G, ZSOMBOKT, BAGDY G: High anxiety and migraine are associated with the s allele of the 5HTTLPR gene polymorphism. Psychiatry Res. (2007) 149(1-3):261-266.
152. GENAZZANI AR, STOMATI M, MORITTU A et al.: Progesterone, progestagens and the central nervous system. Hum. Reprod. (2000) 15(Suppl. 1):14-27.
153. HOGSKILDE S, NIELSEN JW, CARL P, SORENSEN MB: Pregnanolone emulsion. A new steroid preparation for intravenous anesthesia: an experimental study in mice. Anesthesia (1987) 42(6):586-590.
154. BACKSTROM T, GEE KW, LAN N. SORENSEN M, WAHLSTROM G: Steroids in relation to epilepsy and anesthesia. Ciba Found. Symp. (1990) 153:225-230; discussion 230-229.
155. GRUBER CJ, HUBER JC: Differential effects of progestins on the brain. Maturitas (2003) 46(Suppl. 1):S71-S75.
156. A-receptor-mediated effects of progesterone, its ring-A-reduced metabolites and synthetic neuroactive steroids on neurogenic oedema in the rat meninges. Br. J. Pharmacol. (1996) 117(1):99-104.
157. PETITCLERC M, BEDARD PJ, DI PAOLO T: Progesterone releases dopamine in male and female rat striatum: a behavioral and microdialysis study. Prog. Neuropsychopharmacol. Biol. Psychiatry (1995) 19(3):491-497.
158. SINCHAK K, MICEVYCH PE: Progesterone blockade of estrogen activation of μ-opioid receptors regulates reproductive behavior. J. Neurosci. (2001) 21(15):5723-5729.
159. REDDY DS, APANITES LA: Anesthetic effects of progesterone are undiminished in progesterone receptor knockout mice. Brain Res. (2005) 1033(1):96-101.
160. RUPPRECHT R, REUL JM, TRAPP T et al.: Progesterone receptor-mediated effects of neuroactive steroids. Neuron (1993) 11(3):523-530.
161. AMIR BY, YAACOV B, GUY B et al.: Headaches in women undergoing in vitro fertilization and embryo-transfer treatment. Headache (2005) 45(3):215-219.
162. SOMERVILLE BW: The role of estradiol withdrawal in the etiology of menstrual migraine. Neurology (1972) 22(4):355-365.
163. SOMERVILLE BW: Estrogen-withdrawal migraine. I. Duration of exposure required and attempted prophylaxis by premenstrual estrogen administration. Neurology (1975) 25(3):239-244.
164. LICHTEN EM, LICHTEN JB, WHITTY A, PIEPER D: The confirmation of a biochemical marker for women's hormonal migraine: the depo-estradiol challenge test. Headache (1996) 36(6):367-371.
165. STEIN GS: Headaches in the first post partum week and their relationship to migraine. Headache (1981) 21(5):201-205.
166. MACGREGOR EA: Oestrogen and attacks of migraine with and without aura. Lancet Neurol. (2004) 3(6):354-361.
167. EPSTEIN MT, HOCKADAY JM, HOCKADAY TD: Migraine and reporoductive hormones throughout the menstrual cycle. Lancet (1975) 1(7906):543-548.
168. CALHOUN AH: A novel specific prophylaxis for menstrual-associated migraine. South Med. J. (2004) 97(9):819-822.
169. DENNERSTEIN L, MORSE C, BURROWS G et al.: Menstrual migraine: a double-blind trial of percutaneous estradiol. Gynecol. Endocrinol. (1988) 2(2):113-120.